The adverse effects that were significantly more common with topiramate than placebo were paresthesia (50.8% vs. 10.6%), dysgeusia (23.0% vs. 4.8%), anorexia (19.7% vs. 6.9%), difficulty with concentration/attention (14.8% vs. 3.2%), nervousness (14.2% vs. 7.5%), dizziness (11.5% vs. 5.3%), and pruritis (10.4% vs. 1.1%).25 A more detailed analysis of the transient cognitive impairment caused by topiramate showed that it includes mental slowing and modest reductions in verbal fluency and working memory, which are generally dose related.58
